A Phase 4 interventional study of Fluticasone furoate and Placebo in Asthma, sponsored by GlaxoSmithKline. Completed at 55 sites in 6 countries. Open to participants aged 5 Years to 9 Years. Per ClinicalTrials.gov, last updated 2024-01-17.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.
Among the 40 studies testing fluticasone furoate in Asthma, this one is the 10th largest by enrollment, is one of 2 that started in 2017, is one of 6 in phase 4, and was the 31st registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →
fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 5 Years to 9 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 477 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 102 across the 40 interventional studies. Of the 35 that completed or were terminated, 22 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 40 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 44th largest by enrollment of the 238 interventional ones that give a count, is one of 16 that started in 2017, is one of 53 in phase 4, and was the 206th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
1 of the studies testing fluticasone furoate in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies testing fluticasone furoate in Asthma, from their registry updates:
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
There is a regulatory requirement to evaluate the extent of reduction (if any) of growth velocity associated with inhaled corticosteroid (ICS) containing products that are to be administered to children, and to this end there is Food and Drug Administration (FDA) regulatory guidance. This is a randomised, single-blind (run-in period)/double-blind (treatment period), parallel group, placebo controlled, multicentre study to assess the effect of once daily (OD) inhaled fluticasone furoate (FF) 50 microgram (mcg) on growth velocity in prepubertal asthmatic children on a background therapy of open-label montelukast. This study will be conducted over a total duration of approximately 76 weeks: 16-week run-in period (single-blind placebo inhaler), 52-week double-blind treatment period (inhaled FF 50 mcg /placebo administered OD in the morning for 52 weeks) and 8-week follow-up period. The purpose of the study is to evaluate the magnitude of effect (with a level of precision) on growth velocity of prepubertal asthmatic paediatric subjects (aged 5 to \<9 years) following administration of OD inhaled FF 50 mcg for one year. This study fulfills European Union (EU) and United States (US) regulatory requirements for the evaluation of potential growth suppression in children.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Short acting beta-agonist (SABA) inhaler alone (example given [e.g.] salbutamol) on an as needed basis and/or regular non-ICS controller medications for asthma (e.g. cromones or leukotriene receptor antagonists).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During run-in period, subjects will receive inhaled placebo for 16 weeks using ELLIPTA inhaler. Followed by treatment period where subjects will receive inhaled FF 50 mcg administered once daily in the morning for 52 weeks using ELLIPTA inhaler. Subjects will also receive open-label montelukast (4 milligrams \[mg\] for subjects who are 5 years old and 5 mg for subjects who are \>= 6 years old) to be administered as one tablet of montelukast each evening for the duration of the study. Each subject will receive a SABA (albuterol/salbutamol \[inhalation aerosol or nebuliser\]) to be used as needed throughout the entire study period as rescue medication for symptomatic relief of asthma symptoms.
Drug: Fluticasone furoate · Drug: Placebo · Drug: Montelukast · Drug: Short Acting Beta 2 Agonist
During run-in period, subjects will receive inhaled placebo for 16 weeks using ELLIPTA inhaler. Followed by treatment period where subjects will receive inhaled placebo administered once daily in the morning for 52 weeks using ELLIPTA inhaler. Subjects will also receive open-label montelukast (4 milligrams \[mg\] for subjects who are 5 years old and 5 mg for subjects who are \>=6 years old) to be administered as one tablet of montelukast each evening for the duration of the study. Each subject will receive a SABA (albuterol/salbutamol \[inhalation aerosol or nebuliser\]) to be used as needed throughout the entire study period as rescue medication for symptomatic relief of asthma symptoms.
Drug: Placebo · Drug: Montelukast · Drug: Short Acting Beta 2 Agonist
Fluticasone furoate will be supplied as 50 mcg per blister dry white powder for inhalation using ELLIPTA inhaler.
Placebo will be supplied as dry white powder Lactose for inhalation using ELLIPTA inhaler.
Montelukast will be supplied as 4 mg chewable tablet (5 year old subjects) and as 5 mg chewable tablet (\>=6 year old subjects)
Albuterol/salbutamol will be supplied as inhalation aerosol or nebulizer.
Growth Velocity (Centimeter Per Year) Over the Double-blind Treatment Period, as Determined by Stadiometry
Three reproducible height measurements were taken using a stadiometer at each visit and were recorded to nearest 1/10th of centimeter. Each set of triplicate measurements was averaged to derive one estimated height per participant per visit. Growth velocity was calculated for each participant over double-blind treatment period (up to 52 weeks \[wk\]) by fitting a regression line to averaged height measurements at each visit for that participant during period. Slope of this regression line was participant's growth velocity for double-blind treatment period. Treatment policy estimand was assessed, including all on- and post-treatment data. Baseline was included as covariate which was calculated based on stadiometric height measurements recorded at Visits 1(wk -16), 3(wk-8), and 5(wk0), data from at least two of these visits were used to fit a simple linear regression line against time and the slope of the fitted regression line was the participant's Baseline growth velocity.
Time frame: Up to 52 weeks
Percentage of Participants Below the Third Percentile of Growth Velocity During Double-blind Treatment Period
Three reproducible height measurements were taken using stadiometer at each visit\&were recorded to nearest 1/10th of a centimeter.Each set of triplicate measurements was averaged to derive one estimated height per participant per visit.Growth velocity(GV)was calculated for each participant over double-blind treatment(up to 52 weeks)period by fitting regression line to height measurements recorded for that participant during period.Each participant's double-blind(DB) treatment period GV was calculated based on all on \&off treatment height data \&was programmatically compared to data values from Standards from Birth to Maturity for Height,Weight,Height Velocity, established in British Children(1965)\&further updated for North American children(1985)using 3rd percentile value of age closest to participant's age at end of endpoint(i.e.either end of participant's DB treatment period \[Visit18 Wk 52\]/withdrawal from study\[Early Withdrawal Visit\]).Percentage values presented is rounded off.
Time frame: Up to 52 weeks
Percentage of Participants With Change in Growth Velocity Quartiles From Baseline to Endpoint
Growth velocity(GV) quartile(defined as 1st quartile(1Q)=1st-25th percentile,2Q=26th-50th percentile,3Q=51st-75th percentile,4Q=76th-100th percentile) was determined at Baseline\&endpoint.Endpoint was defined as slope of simple linear regression of average stadiometric height recorded at week 28\& upto wk52.Baseline growth velocity was calculated as slope from simple linear regression of average stadiometric height recorded at wk-16,-8\&0.Baseline GV was programmatically compared to reference for standard height data using participant's estimated age at wk0\& age in reference data closest to actual age of participant to determine Baseline GV quartile.Endpoint GV was programmatically compared to reference data using participant's age at endpoint \& age in reference data that was closest to actual age of participant to determine endpoint GV quartile. Any increase/decrease indicates any increase/decrease in quartiles with reference to Baseline. Percentage values presented is rounded off.
Time frame: Baseline and Endpoint (Week 28[Visit 12] up to and including Week 52 [Visit 18])
Growth Velocity Over the First 12 Weeks of Double-blind Treatment Period
Growth velocity was calculated for each participant over double blind period by fitting regression line to height measurements recorded for that participant during period.Slope of this regression line was participant's growth velocity for double-blind treatment period.In order to be included in this analysis,participant must have data from Visit8(Wk 12) stadiometric height assessment.Baseline was included as covariate which was calculated based on stadiometric height measurements recorded at Visits 1(wk -16),3(wk-8),\& 5(wk0),data from at least two of these visits were used to fit simple linear regression line against time\&slope of fitted regression line was participant's Baseline growth velocity.All available height data collected during double-blind treatment period upto Visit8(Wk12) while participant was on randomized double-blind treatment was considered.ANCOVA model was used to estimate mean treatment difference in growth velocity over 1st 12weeks of double-blind treatment period.
Time frame: Up to 12 weeks (Visit 8) of double-blind treatment period
Change in Height Standard Deviation Scores (SDS) From Baseline to Endpoint
Each participant's SDS for each of three required stadiometric height measurements was calculated as:(observed height measurement-standard median height for age at Visit \[week-16\]) divided by (/) (\[standard 95th height percentile for age at visit-standard 5th height percentile for age at visit\]/\[2\*1.645\]).Standard median, 95th percentile, \& 5th percentile values were obtained from standard tables (Guidance for Industry Orally Inhaled \& Intranasal Corticosteroid). SDS for each height stadiometric measurement at each visit was calculated using percentiles from standard tables \& averaged for each participant before being summarized by treatment group. A reduction in SDS over time indicates growth deceleration \& an increase in SDS over time means growth acceleration.Baseline was defined as height SD score at Visit 5 (week 0). Endpoint was defined as height SD score at Visit 18 (week52) (on- \& off-treatment data). Change from Baseline was calculated as Endpoint value minus Baseline value.
Time frame: Baseline (Week 0 [Visit 5]) and up to Endpoint (Week 52 [Visit 18])
Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose which results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations as per investigator's judgement.
Time frame: Up to 76 weeks
Number of Participants With On-treatment Asthma Exacerbations Over Double-blind Treatment Period
An exacerbation is defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or a single depot corticosteroid injection, or an in-patient hospitalization or emergency department (ED) visit due to asthma that required systemic corticosteroids. Number of participants with on-treatment asthma exacerbations during double-blind treatment period is presented.
Time frame: Up to 52 weeks
This was a multicenter, randomized, double-blind, placebo-controlled study to evaluate the effects of a one-year regimen of orally inhaled fluticasone furoate (FF) 50 micrograms (mcg) once daily on growth velocity in prepubertal, pediatric participants with asthma.
| Milestone | Placebo | FF 50 mcg |
|---|---|---|
| Started | 239 | 238 |
| Completed | 196 | 205 |
| Not completed | 43 | 33 |
| Withdrew: Withdrawal by subject | 30 | 21 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Site closed | 12 | 11 |
Three reproducible height measurements were taken using a stadiometer at each visit and were recorded to nearest 1/10th of centimeter. Each set of triplicate measurements was averaged to derive one estimated height per participant per visit. Growth velocity was calculated for each participant over double-blind treatment period (up to 52 weeks \[wk\]) by fitting a regression line to averaged height measurements at each visit for that participant during period. Slope of this regression line was participant's growth velocity for double-blind treatment period. Treatment policy estimand was assessed, including all on- and post-treatment data. Baseline was included as covariate which was calculated based on stadiometric height measurements recorded at Visits 1(wk -16), 3(wk-8), and 5(wk0), data from at least two of these visits were used to fit a simple linear regression line against time and the slope of the fitted regression line was the participant's Baseline growth velocity.
| Centimeter per year | Placebo | FF 50 mcg |
|---|---|---|
| Growth Velocity (Centimeter Per Year) Over the Double-blind Treatment Period, as Determined by Stadiometry | 6.065 ± 0.1090 | 5.905 ± 0.1078 |
Three reproducible height measurements were taken using stadiometer at each visit\&were recorded to nearest 1/10th of a centimeter.Each set of triplicate measurements was averaged to derive one estimated height per participant per visit.Growth velocity(GV)was calculated for each participant over double-blind treatment(up to 52 weeks)period by fitting regression line to height measurements recorded for that participant during period.Each participant's double-blind(DB) treatment period GV was calculated based on all on \&off treatment height data \&was programmatically compared to data values from Standards from Birth to Maturity for Height,Weight,Height Velocity, established in British Children(1965)\&further updated for North American children(1985)using 3rd percentile value of age closest to participant's age at end of endpoint(i.e.either end of participant's DB treatment period \[Visit18 Wk 52\]/withdrawal from study\[Early Withdrawal Visit\]).Percentage values presented is rounded off.
| Percentage of participants | Placebo | FF 50 mcg |
|---|---|---|
| Percentage of Participants Below the Third Percentile of Growth Velocity During Double-blind Treatment Period | 9 | 7 |
Growth velocity(GV) quartile(defined as 1st quartile(1Q)=1st-25th percentile,2Q=26th-50th percentile,3Q=51st-75th percentile,4Q=76th-100th percentile) was determined at Baseline\&endpoint.Endpoint was defined as slope of simple linear regression of average stadiometric height recorded at week 28\& upto wk52.Baseline growth velocity was calculated as slope from simple linear regression of average stadiometric height recorded at wk-16,-8\&0.Baseline GV was programmatically compared to reference for standard height data using participant's estimated age at wk0\& age in reference data closest to actual age of participant to determine Baseline GV quartile.Endpoint GV was programmatically compared to reference data using participant's age at endpoint \& age in reference data that was closest to actual age of participant to determine endpoint GV quartile. Any increase/decrease indicates any increase/decrease in quartiles with reference to Baseline. Percentage values presented is rounded off.
| Percentage of Participants | Placebo | FF 50 mcg |
|---|---|---|
| Any increase | 33 | 32 |
| Any decrease | 34 | 38 |
Growth velocity was calculated for each participant over double blind period by fitting regression line to height measurements recorded for that participant during period.Slope of this regression line was participant's growth velocity for double-blind treatment period.In order to be included in this analysis,participant must have data from Visit8(Wk 12) stadiometric height assessment.Baseline was included as covariate which was calculated based on stadiometric height measurements recorded at Visits 1(wk -16),3(wk-8),\& 5(wk0),data from at least two of these visits were used to fit simple linear regression line against time\&slope of fitted regression line was participant's Baseline growth velocity.All available height data collected during double-blind treatment period upto Visit8(Wk12) while participant was on randomized double-blind treatment was considered.ANCOVA model was used to estimate mean treatment difference in growth velocity over 1st 12weeks of double-blind treatment period.
| Centimeter per year | Placebo | FF 50 mcg |
|---|---|---|
| Growth Velocity Over the First 12 Weeks of Double-blind Treatment Period | 6.222 ± 0.1845 | 6.281 ± 0.1841 |
Each participant's SDS for each of three required stadiometric height measurements was calculated as:(observed height measurement-standard median height for age at Visit \[week-16\]) divided by (/) (\[standard 95th height percentile for age at visit-standard 5th height percentile for age at visit\]/\[2\*1.645\]).Standard median, 95th percentile, \& 5th percentile values were obtained from standard tables (Guidance for Industry Orally Inhaled \& Intranasal Corticosteroid). SDS for each height stadiometric measurement at each visit was calculated using percentiles from standard tables \& averaged for each participant before being summarized by treatment group. A reduction in SDS over time indicates growth deceleration \& an increase in SDS over time means growth acceleration.Baseline was defined as height SD score at Visit 5 (week 0). Endpoint was defined as height SD score at Visit 18 (week52) (on- \& off-treatment data). Change from Baseline was calculated as Endpoint value minus Baseline value.
| Standard Deviation Score | Placebo | FF 50 mcg |
|---|---|---|
| Change in Height Standard Deviation Scores (SDS) From Baseline to Endpoint | -0.02 ± 0.281 | -0.04 ± 0.281 |
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose which results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations as per investigator's judgement.
| Participants | Placebo | FF 50 mcg |
|---|---|---|
| Any SAEs | 8 | 6 |
| Any Non-serious AEs | 105 | 99 |
An exacerbation is defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or a single depot corticosteroid injection, or an in-patient hospitalization or emergency department (ED) visit due to asthma that required systemic corticosteroids. Number of participants with on-treatment asthma exacerbations during double-blind treatment period is presented.
| Participants | Placebo | FF 50 mcg |
|---|---|---|
| Number of Participants With On-treatment Asthma Exacerbations Over Double-blind Treatment Period | 22 | 7 |
Collected over All cause mortality, non-serious adverse events (AEs) and serious AEs were collected up to 76 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/239 (0%) | 8/239 (3.3%) | 105/239 (43.9%) |
| FF 50 mcg | 0/238 (0%) | 6/238 (2.5%) | 99/238 (41.6%) |
| Event | Placebo | FF 50 mcg |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 2/239 | 0/238 |
| FaecalomaGastrointestinal disorders | 0/239 | 1/238 |
| Adenoviral haemorrhagic cystitisInfections and infestations | 0/239 | 1/238 |
| AppendicitisInfections and infestations | 0/239 | 1/238 |
| BronchitisInfections and infestations | 0/239 | 1/238 |
| PneumoniaInfections and infestations | 1/239 | 1/238 |
| TonsillitisInfections and infestations | 0/239 | 1/238 |
| HaematuriaRenal and urinary disorders | 0/239 | 1/238 |
| Gastroenteritis norovirusInfections and infestations | 1/239 | 0/238 |
| Urinary tract infectionInfections and infestations | 1/239 | 0/238 |
| Event | Placebo | FF 50 mcg |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 33/239 | 29/238 |
| NasopharyngitisInfections and infestations | 25/239 | 23/238 |
| PyrexiaGeneral disorders | 18/239 | 13/238 |
| RhinitisInfections and infestations | 18/239 | 16/238 |
| CoughRespiratory, thoracic and mediastinal disorders | 15/239 | 12/238 |
| BronchitisInfections and infestations | 12/239 | 9/238 |
| HeadacheNervous system disorders | 12/239 | 10/238 |
| InfluenzaInfections and infestations | 7/239 | 11/238 |
| Respiratory tract infection viralInfections and infestations | 4/239 | 10/238 |
| PharyngitisInfections and infestations | 9/239 | 3/238 |
| Age, Continuous(Years) | Placebo | FF 50 mcg | Total |
|---|---|---|---|
| Mean | 6.1 ± 1.07 | 6.3 ± 1.02 | 6.2 ± 1.05 |
| Sex: Female, Male(Participants) | Placebo | FF 50 mcg | Total |
|---|---|---|---|
| Female | 84 | 94 | 178 |
| Male | 155 | 144 | 299 |
| Race/Ethnicity, Customized(Participants) | Placebo | FF 50 mcg | Total |
|---|---|---|---|
| African American/African Heritage | 13 | 13 | 26 |
| Asian - Central/South Asian Heritage | 0 | 1 | 1 |
| Multiple | 18 | 20 | 38 |
| White - Arabic/North African Heritage | 3 | 3 | 6 |
| White - Mixed Race | 1 | 0 | 1 |
| White - White/Caucasian/European Heritage | 204 | 201 | 405 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk.com
Ran from Jul 2017 to primary completion in Apr 2021, 44 months.
Results were first posted in Jan 2022, 8 months after primary completion.
Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 44 months is above that.
Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone furoate